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ABO blood groups have been associated with various disease phenotypes, particularly cardiovascular diseases. Cardiovascular
diseases are the most common causes of death in developed countries and their prevalence rate is rapidly growing in developing
countries. There have been substantial historical associations between non-O blood group status and an increase in some
cardiovascular disorders. Recent GWASs have identiﬁed ABO as a locus for thrombosis, myocardial infarction, and multiple
cardiovascular risk biomarkers, refocusing attention on mechanisms and potential for clinical advances. As we highlight in this
paper, more recent work is beginning to probe the molecular basis of the disease associations observed in these observational
studies. Advances in our understanding of the physiologic importance of various endothelial and platelet-derived circulating
glycoproteins are elucidating the mechanisms through which the ABO blood group may determine overall cardiovascular disease
risk. The role of blood group antigens in the pathogenesis of various cardiovascular disorders remains a fascinating subject with
potential to lead to novel therapeutics and prognostics and to reduce the global burden of cardiovascular diseases.
1.Introduction
In 1901, Landsteiner identiﬁed ABO blood groups as the
ﬁrst recognized human blood group system. The clinical
signiﬁcance of ABO blood type extends beyond transfusion
medicine and solid organ/hematopoietic transplantation. To
date, numerous reports have suggested important associa-
tions between ABO blood groups and various diseases, for
example, gastric cancer [1], periodontal diseases [2], and
cardiometabolic diseases [3, 4].
According to World Health Organization (WHO) data,
cardiovascular diseases (CVDs) are and will remain the
leading causes of death globally: an estimated 17.3 million
people died from CVD in 2008, representing 30% of all
global deaths (WHO Media Centre (2011), cardiovascular
diseases (fact sheet). retrieved from http://www.who.int/
mediacentre/factsheets/fs317/en/index.html). Studies on the
associations between CVD and ABO blood groups have a
longhistory.In1955,Woolfproposedanoddsratioasamea-
sure to quantify the disease risk conferred by blood group
type [5]. In 1969, Jick et al. reported a deﬁcit of patients with
blood group O among those who received anticoagulants for
venous thromboembolism [6]. Prior to mutation detection
in haemophilia carriership analysis, likelihood ratios of
carriership of hemophilia A were based on Factor VIII levels
conditional on blood group [7]. A number of later studies
elucidated that ABO blood groups, particularly non-O blood
groups, are associated with major cardiovascular risk factors
and/or increased rate of cardiovascular events [8–13]. How-
ever, there is limited consensus regarding the magnitude and
signiﬁcance of the ABO eﬀects at the population level, and
whether it relates to all disorders equally or predominantly
modulates thrombotic pathways and disorders [14]. This
paper summarizes the basic concepts of the biochemistry of
ABO blood groups and recent ﬁndings of their relations to
CVD.2 International Journal of Vascular Medicine
2. Biochemistry andPopulation
Distribution of ABO Blood Groups
The ABO blood group is determined by the presence of A
and B antigens on the surface of the red blood cells (RBCs).
In addition to RBCs, these antigens are widely expressed on
the membranes of a wide variety of cells, including platelets,
vascular endothelium and epithelium [15]a sw e l la si ns a l i v a
and body ﬂuids [16]. The biochemistry of the ABO blood
group system has been reviewed recently [16]. Brieﬂy, the
ABH blood group antigens consist of terminal carbohydrate
molecules which are synthesized by the sequential action
of the ABO glycosyltransferases. The ABO glycotransferase
(transferase A, alpha 1,3-N-acetylgalactosaminyltransferase;
transferase B, alpha 1,3-galactosyltransferase) gene encodes
proteinsrelatedtotheABObloodgroupsystem[17,18].The
active ABO glycotransferases catalyze the addition of speciﬁc
monosaccharidestoacommoncoreprecursorantigen(H)to
formdistinctAandBantigens.Individualswithbloodgroup
O express only the basic H antigen [19]d u et oad e l e t i o n
of guanine-258 in the region of the gene encoding the N-
terminus of the protein which results in a frameshift and
translation of a protein lacking glycosyltransferase activity
[17, 18].
The frequency of the common ABO phenotypes varies
among diﬀerent populations. Populations with a high fre-
quency of the A phenotype are found mainly in Northern
and Central Europe [18] .T h eBp h e n o t y p ei sm o s tf r e q u e n t
inCentralAsia[18].BloodgroupOisthemostfrequentphe-
notype globally, with parts of Africa and Australia showing
highest frequencies [18]. The reasons for the observed diﬀer-
ences among populations are not well understood, although
several theories have been proposed. Evolutionary selection
based on pathogen-driven blood group antigen changes may
be one of the major contributors [18]. Under this theory,
terminal carbohydrate modiﬁcation on host proteins, lipids,
and cells plays a signiﬁcant role in modulating interactions
with pathogens. Thus, ambient pathogens are thought to
have driven the regional evolution and selection of host
blood group antigens that provide survival advantage to
distinct geographic pathogen exposures.
3. Genome-WideAssociationStudies
Conﬁrmed ABO as a Locus for
VenousThromboembolism and
MyocardialInfarction
The widespread use of genome-wide association studies
(GWASs) over the last 5 years has spurred an enormous
acceleration in discoveries across the entire spectrum of
CVD [20]. Recent GWASs have conﬁrmed ABO as a locus
for venous thromboembolism (VTE), myocardial infarction
(MI), and multiple cardiovascular biomarkers (Table 1).
One of the most studied aspects of the ABO gene is
its relationship with von Willebrand factor (VWF) [17, 36,
37]. In 2003, a family-based linkage screen was carried
out to determine the loci involved in VWF variation in
398 Spanish individuals. Markers at the chromosome 9q
ABO locus region harbored the highest LOD value of
3.46 [38]. Subsequently, several GWASs have shown that
carriers of single nucleotide polymorphisms (SNPs) that
mark non-O blood group types have higher levels of plasma
VWF when compared to O individuals. A recent GWAS
of 7856 European participants in the Atherosclerosis Risk
In Communities (ARIC) cohort study showed that ABO
blood group O carriers had a 25% average reduction in
plasmaVWFlevelswhencomparedwithnon-Obloodgroup
carriers. SNP rs514659, which was used to tag the O blood
type, contributed to 15.4% of circulating VWF variance
[33].Additionally, agenome-widemeta-analysisof4cohorts
found that rs657152, which also tags the blood group O,
was strongly associated with circulating VWF levels and
that blood group O individuals had 22–30% lower plasma
VWF when compared to non-blood group O individuals
[28]. A relationship between Factor VIII (FVIII) plasma
concentrations and ABO blood groups has also been seen.
However, in a Cohorts for Heart and Aging Research in
Genome Epidemiology (CHARGE) Consortium GWAS, no
unique genetic variants within the ABO locus were found to
aﬀect FVIII independently of VWF [34]. As VWF binds and
transports FVIII, the correlation between the ABO gene and
FVIII is most likely mediated via VWF [39].
As increased plasma levels of VWF and Factor VIII are
associated with greater risk of thrombosis [40, 41], many
studies have examined the connection between ABO blood
group and thrombotic risk. In a GWAS published in 2009,
SNPs rs8176750, rs8176746 and rs8176719, which tag the
A2, B, and O ABO blood groups, respectively, showed that
genetically inferred blood type O had 67% lower risk of
VTE than non-O blood groups. Additionally, the A2 blood
group had 47% lower risk of VTE when compared to the
other non-O blood group phenotypes [32]. Blood type A2
was also shown to be associated with lower VTE risk in
a recently published GWAS involving 1,503 VTE patients
in which rs8176704 was used to tag the A2 blood group
[23]. These data suggest that the decreased risk of VTE
is a result of reduced H antigen glycosylation, as the A2
allele contains a 1061delC that results in the synthesis of
an enzyme that has 30–50 fold less A transferase activity
than the A1 allele product [42]. Blood group genotypes
may be more informative than blood group phenotypes in
studying the association between blood groups and VTE
since genotypes can distinguish between heterozygous and
h o m o z y g o u sc a r r i e r so fA ,B ,a n dOa l l e l e sa n db e t w e e n
A1 and A2 alleles [43, 44]. One GWAS found that the A11
allele, tagged by rs529565 and rs657152, and the B allele,
tagged by rs8176749, were associated with 56% and 16%
increased risk of VTE, respectively, when compared to the
O11 allele. Moreover, when compared with carriers of the
O1O1 diplotype, VTE risk was increased by 79% for the A11
diplotype, 82% for the B diplotype, and 170% for the AB
diplotype carriers. Overall, non-O categories combined were
associated with a 77% increased risk of VTE when compared
to the O category [29]. The eﬀect of ABO genotype on
thrombosis risk was also investigated in a case-control study
of471patientsand471controlsoftheLeidenThrombophilia
Study(LETS)whichrevealedthatnon-OOgenotypes,exceptInternational Journal of Vascular Medicine 3
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homozygous A2 and A2-O combinations, were associated
with increased thrombotic risk when compared to OO
genotypes. The relative thrombotic risk of AB genotypes
and A1-combinations was increased by 90–110% when
compared to OO genotypes and the relative thrombotic risk
of the homozygous B genotype and B-O combinations was
increased by 60% [45].
The ABO locus has also been associated with arterial
thrombosis in studies of MI. Our group reported that all
11 SNPs that exceeded genome-wide signiﬁcance for MI in
patients with established coronary atherosclerosis mapped to
the ABO locus. The risk alleles at rs514659 (odds ratio 1.21;
P = 7.62 × 10
−9) and rs687289 (odds ratio 1.19; P = 7.75 ×
10
−9) were perfect tags for the loss of function ABO O blood
group demonstrating that functional ABO glycotransferases
conferred increased risk of MI. Further analysis found
that rs514659 was associated with coronary artery diseases
(CADs) when complicated by MI but not with CAD without
MI, suggesting that the primary relationship of ABO to
clinical CAD is through modulation of coronary thrombosis
or plaque rupture in patients with established coronary
atherosclerosis rather than through primary promotion of
atherosclerosis per se.
The increase in MI risk for non-O blood type individuals
has been suggested for some time through epidemiological
studies, although there has been debate as to which ABO
blood group phenotypes confer the largest increase in risk
[8, 11, 46–49]. Just recently, He et al. reported results of two
large prospective studies of incident coronary heart disease
(CHD) as well as a meta-analysis of all prospective data [50].
The Nurses’ Health Study (including 62,073 women ages
30 to 55 at baseline) and the Health Professionals Follow-
up Study (including 27,428 men ages 40 to 75 at baseline)
were followed up to 2006 and recorded 2,055 cases of CHD
in the two cohorts. Individuals with self-reported non-O
b l o o dt y p eh a da na g e - a d j u s t e dh a z a r dr a t i o( H R )o f1 . 0 9
(95% CI 1.03 to 1.17, P = 0.005) for risk of developing
CHD. Associations between blood type and CHD risk were
not modiﬁed by age, physical activity, alcohol consumption,
smoking status, or diabetes history. A meta-analysis of an
additional six prior cohorts, for a combined total of 114,648
individuals and 5,741 CHD cases, also showed a signiﬁcant
pooled relative risk for CHD in patients with non-O blood
type of 1.11 (95% CI 1.05 to 1.18, P = 0.001). Among
participants in the cohort, those with type O blood were
signiﬁcantly less likely to develop CHD when compared
against types B (HR 1.11, 95% CI 1.01 to 1.23) and AB (HR
1.23, 95% CI 1.10 to 1.37), with a trend toward a higher risk
for patients with type A blood (HR 1.05, 95% CI 0.98 to
1.13).
It is plausible that ABO modulation of VWF-related
thrombosis accounts for the ABO association with MI.
However,ABOantigensareexpressedalsoondistinctplatelet
proteins, including GPIIb, a subunit of the ﬁbrinogen
receptor heterodimer [51–54], and may therefore modulate
speciﬁc platelet functions in arterial thrombosis and MI
(see below). In addition, ABO modulation of atherosclerotic
plaque rupture and atherosclerosis itself cannot be discount-
ed without further study.
4.Associationsof the ABOLocus with
Markersof EndothelialFunctionand
SerumLipoproteins
The ABO glycotransferase may have broader impact on
atherosclerotic CVD than simply through modulation of
thrombosis. A series of GWAS have linked the ABO locus to
circulating levels of soluble intercellular adhesion molecule-
1 (sICAM-1), soluble P-selectin (sP-selectin), and soluble E-
selectin (sE-selectin). Notably, mechanistic studies in rodent
modelshaveimplicatedtheseproteinsinatherosclerosis[55–
59] and their blood levels in humans correlate with increased
risk of CVD events [60, 61]. Par´ e et al. showed that SNP
rs507666, located in Intron 1 of the ABO gene and a perfect
tag for ABO blood group A1, was associated with decreased
levels of sICAM-1 (P = 5.1 × 10
−29) when compared to
the O allele and contributed to 1.5% of the total sICAM-
1 concentration variance [31] .T h es a m eg r o u pc o n ﬁ r m e d
this relationship between rs507666 and circulating sICAM-1
levels in a larger GWAS published in 2011 [30]. Blood levels
ofsP-selectinandsE-selectinarealsoassociatedwithSNPsin
the ABO region [21, 22, 25]. A recent meta-analysis showed
that, compared with major allele homozygotes, heterozygote
and minor allele homozygote individuals for the rs507666,
rs579459, and rs651007 SNPs, which demonstrate a high
degree of linkage disequilibrium with each other (r2 ∼ 0.96)
and tag the ABO A1 subtype, had lower plasma levels of
sICAM-1, sP-selectin, and sE-selectin [27]. A recent GWAS
has also identiﬁed a potential relationship between ABO
and circulating levels of angiotensin-converting enzyme
(ACE); when compared to the ABO blood group O, mean
ACE activity in carriers of blood group B was signiﬁcantly
increased(P = 2.3×10
−10)whileACEactivityinbloodgroup
Aw a sd e c r e a s e d( P = 1.5 ×10
−8)[ 24].
Past epidemiological studies, some dating as far back as
50 years ago, have suggested evidence for ABO association
with circulating levels of cholesterol, with non-O groups
appearing to have higher levels [47, 62–65]. For example, in
1976,Garrisonetal.publishedanepidemiologicalanalysisin
the Framingham Heart Study showing consistent elevations
of serum cholesterol levels in non-O blood groups when
compared to the O blood group [47]. Some recent GWASs
and their meta-analyses support this potential role for
ABO genotypes in modulating circulating levels of total
and LDL cholesterol, as well as phytosterols, established
causal risk factors for atherosclerotic heart diseases [26, 35,
66]. A meta-analysis of 46 lipid based GWAS reported an
association between ABO SNPs and serum cholesterol levels.
Total cholesterol was increased by 2.3mg/dL in heterozygote
individuals for the ABO rs651007 SNP when compared to
major allele homozygotes (P = 8.66 × 10
−21), while LDL
cholesterol was increased by 2.05mg/dL in heterozygote
individuals for the ABO rs649129 SNP when compared
to major allele homozygotes (P = 7.85 × 10
−22)[ 26]. A
GWAS published in 2010 found that the ABO locus showed
genome-wide-signiﬁcance for association with phytosterol
levels. Speciﬁcally, rs657152, which tightly tags the O1
allele, was found to be associated with decreased levels ofInternational Journal of Vascular Medicine 7
circulating phytosterols. In a separate analysis, the study
reported that individuals with the O allele had decreased
campesterol concentrations when compared to the A and
B alleles. Furthermore, additional analyses revealed that
rs657152 was associated with reduced CAD risk (P =
4.0 × 10
−5) when compared to alleles that were associated
with increased phytosterols [35]. These epidemiological and
genetic associations of ABO blood type with levels of
circulating lipoproteins and sterols underscore the need for
functional studies that deﬁne the mechanistic basis of these
relationships and the potential for therapeutic translation.
Overall, these pleiotropic associations with cardiovas-
cular risk biomarkers suggest a complex role of ABO in
atheroscleroticandvasculardiseaseswithdistinctABOgeno-
types and ABO functions contributing to multiple causal
pathways, for example, ABO genotypes related to blood
group O and loss of glycotransferase function protect against
VTE and MI while distinct genotypes relating to speciﬁc
A and B blood subgroups and glycotransferase functions
may have a more subtle and distinct impact on endothelial
function, lipoproteins, and atherosclerosis (Table 1).
One paradox that has limited clinical interpretation of
GWAS discoveries, including that for the ABO locus, relates
to the highly signiﬁcant P values reported for common dis-
ease variants despite very small eﬀect sizes (e.g., odds ratio).
Unlike rare disease causing mutations, common variants
for complex diseases have either minor functional eﬀects
or are simply crude markers for rare functional variants;
their strength of association with disease is often very small
despite highly signiﬁcant P values (which relate mostly to
the sample size of GWAS). However, the weak eﬀect sizes of
these variants should not be mistaken for a lack of clinical
importance of a particular gene (or protein/biomarker) or
its therapeutic manipulation in a complex disease process.
For example, rare variants in 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) reductase have quite weak associations
with LDL cholesterol (LDL-C) levels and are well down the
list of top GWAS ﬁndings for LDL-C [26]. Thus, rather than
attempting to infer clinical relevance based on the strength
of associations, the key importance of GWAS is simply to
identify novel genes and proteins for human disease that
warrant further study to establish their mechanistic role
and clinical importance. Over time, the totality of evidence
derived from human, animal, and functional studies allows
an interpretation of the clinical and therapeutic importance
of the initial signiﬁcance level for a locus in a GWAS, the
magnitude of eﬀect on a protein level, and the relative
risk of a given protein level for a disease phenotype. For
the ABO locus, further mechanistic and functional studies
are required in order to deﬁne the clinical and therapeutic
possibilities.
5. PotentialMechanismsfor the
AssociationbetweenABO and CVD
Following recent GWAS discoveries, there is a resurgent
interest in identifying the mechanistic links underlying the
association of the ABO locus and glycotransferase functions
with CVD. Most attention until recently was focused on
the role of ABO in regulating VWF bioactivity and related
thrombotic pathways, but emerging work is deﬁning more
broadly the role of ABO glycotransferase activity in mod-
ulating multiple endothelial, platelet, and cardiometabolic
pathways and exploring whether these eﬀects are causally
involved in cardiometabolic diseases.
5.1. VWF and FVIII as Candidate Mechanisms. VWF and
FVIII are glycoproteins (GPs) that circulate together in
normal plasma as a noncovalent complex and both play
important roles in normal hemostasis. VWF is a carrier
for FVIII and protects it from inactivation. VWF recruits
platelets to the site of clot formation during primary
hemostasis. Factor VIII is released from VWF by the action
of thrombin and participates in the coagulation cascade.
Thus, both VWF and FVIII are key proteins in the formation
of occlusive thrombi in injured vessels [67]. As described
in preceding sections, relative to non-group O, carriers of
ABO blood group O have signiﬁcantly lower circulating
plasma VWF and FVIII levels [68]. Although this clinically
important eﬀect of ABO group on plasma VWF-FVIII levels
is well established, the mechanism through which it is
mediated is not completely resolved. ABO appears to have
direct functional eﬀects on circulating VWF and indirectly
(via inﬂuence of VWF levels) modulates FVIII levels. The
presence of abundant ABH carbohydrate molecules on the
VWF oligosaccharide side chains provides the mechanistic
basis for ABO regulation of VWF levels. The active ABO A
and B glycotransferase enzymes, found in Golgi of endothe-
lial cells, generate terminal carbohydrate modiﬁcations, A
and B antigens, on the existing VWF “H” oligisacharides,
whereas the enzymatically inactive ABO O protein cannot
modify these VWF H antigens. The addition of A or B
terminal carbohydrate antigens to VWF in endothelial cells
might inﬂuence circulating VWF levels and function by
several mechanisms: altering the rate of VWF synthesis
and/or secretion, regulating VWF proteolysis induced by its
major protease, ADAMTS13, modulating VWF clearance,
or changing VWF biological activity: or perhaps some
combination of these events [17]. A number of studies
suggest that it is unlikely that ABO eﬀects on VWF levels
are mediated by alterations in the biosynthesis and secretion
of VWF [17]. In contrast, it has been demonstrated that
the activity of ADAMTS13 diﬀers against VWF of diﬀerent
blood groups, with both the level of ADAMTS13 activity
[69], and the rate of VWF proteolysis by ADAMTS13
[70], being higher in blood group O as compared to
non-O individuals. Thus, the absence of VWF terminal
carbohydrate modiﬁcations in individuals with ABO blood
group O increases the susceptibility to and rate of proteolysis
by ADAMTS13, although data available so far are not in
support of the role of proteolysis by ADAMTS13 in VWF
clearance from the circulation [71]. Due to their physical
association in blood, lower circulating VWF results in lower
levels of FVIII. Whether VWF in platelets (a relatively
abundant source) undergoes any modiﬁcation by ABO
remains controversial; such modiﬁcation could alter platelet8 International Journal of Vascular Medicine
production and subsequent turnover of VWF, particularly
locally during platelet-driven arterial thrombosis, although
this remains to be established. Indeed, current knowledge
suggests that ABO does not modify platelet VWF [72], but
the role of ABO in regulating platelet VWF and platelet
function in thrombosis requires greater study (see below).
5.2. Other Endothelial Molecules and Platelet Proteins as
Potential Mediators. Soluble levels of multiple adhesion
molecules, mostly derived from endothelial cells and
platelets, have been associated with coronary heart disease
[61], and other cardiovascular conditions [73]. In large-
scale genomic studies, plasma levels of sP-selectin and
sICAM-1 were associated with ABO gene variants, but no
association was found between platelet-bound P-selectin
levels and ABO blood group, suggesting that the ABO
blood group may inﬂuence proteolysis and clearance from
the circulation, rather than its production and cellular
presentation [25]. However, the speciﬁc mechanisms of
ABO regulation of circulating levels of these endothelial
GPs are largely unknown. Further, the implications for
their function in atherosclerosis and clinical CVD require
elucidation.
Blood group ABO antigens are known to be carried
by several platelet GPs, for example, GPIb, GPIIb, GPIIIa,
and platelet endothelial cell adhesion molecule (PECAM)
[53], that play important roles in platelet function. Platelet
ABH expression is a stable, donor-speciﬁc characteristic
with 5% of A1 donors typing as either ABH high- or low-
expressers [74], with high levels of A antigen on various
GPs from high-expresser platelets, especially GPIIb and
PECAM (CD31) [51]. GPIIb is an integral component
of the GPIIb-GPIIIa ﬁbrinogen receptor complex, which
represents the critical ﬁnal common pathway for platelet-
driven thrombosis in hemostasis and pathologic arterial
thrombosis including acute MI. Genetic variation in GPIIb
that modulates ﬁbrinogen binding has been associated
with altered risk of thrombosis and MI [75–77], so it
is conceivable that ABO-driven carbohydrate modiﬁcation
of GPIIb might alter its functional interactions with ﬁb-
rinogen and thus platelet-mediated thrombosis. However,
this hypothesis has not been adequately addressed to date.
Besides GPIIb and PECAM, blood group A antigen is also
expressed on other uncharacterized platelet proteins (70–
90kDa) having electrophoretic mobilities closely resem-
bling those of GPIV and GPV [52]. Thus these and
other uncharacterized ABO-expressing platelet proteins may
also act as potential functional modulators of the ABO
associations with arterial thrombosis and cardiovascular
events.
The list of GPs carrying blood type ABO antigens is
growing. Some of the most abundantly expressed GPs, such
as PECAM and VWF, represent major proteins recognized
to carry ABO antigens. However, there is a great need to
identify all ABO target proteins and glycolipids in order to
understand the nature and/or properties of GPs carrying
ABO antigens and to reveal novel, potentially cell-speciﬁc,
mediators of CVD.
6.Perspectives
Despite the relative simplicity of the A and B antigens, espe-
ciallyconsideringthemodestbiochemicaldiﬀerencebetween
them, the ABO blood group system appears to be one of the
most interesting, both clinically and scientiﬁcally. It divides
the world’s population into four major groups. The common
frequency of each major blood group, especially blood group
O (the loss of glycotransferase function ABO type), suggests
important evolutionary selection pressures distinct from
heart disease which now have subtle but signiﬁcant impact
at the population level on complex diseases in modern
society. Much larger epidemiological and genetic studies are
required to determine risks of CVD with particular major
and minor ABO blood group. Such human data will inform
translational and mechanistic studies by pointing to speciﬁc
ABO glycan modiﬁcations that appear to be the drivers
of increased or decreased risk. However, such studies are
inherently limited because they fail to illuminate the speciﬁc
cell/tissue where glycan modiﬁcations are mediating their
actions and do not deﬁne the proteins or lipids carrying
such modiﬁcations that are functionally altered and mediate
disease.
In future studies, it is of critical importance to establish
clear mechanistic basis for the association between ABO
blood groups and CVD. Advances in our understanding
of the physiologic importance of the glycan structures of
VWF have provided a model and elucidated one mechanism,
possibly the major one, through which ABO blood group
determines risk of thrombosis and acute cardiovascular
events. However, there are several other known endothelial
and platelet GPs, discussed above, that are potentially func-
tionally modiﬁed by ABO and candidate causal mediators
in atherosclerosis and CVD. How and where these proteins
aremodiﬁedandwhethertheircarbohydratealterationshave
functional impact on disease requires further study. The
increased risks associated with non-O blood groups might
be attributed to higher levels or functional modiﬁcation
of speciﬁc endothelial-derived GPs, speciﬁc platelet GPs,
both sources, and/or GPs from additional cells and tissues
although leukocytes are not likely primary sources as they
lack the ABO enzyme [78].
The study of glycobiology in complex disease is in
its relative infancy. Unbiased approaches are required to
discover and identify the population of proteins and lipids
that are modiﬁed by ABO (and other glycotransferases), in
cells and tissues of speciﬁc relevance to atherothrombosis, so
that we can deﬁne all potential mediators of speciﬁc aspects
of risk and speciﬁc disease manifestations. Technological
and bioinformatics advances, including mass-spectrometric
approaches, are beginning to emerge which will permit such
unbiased work. The tissue-speciﬁc expression and function
of ABO and many known glycotransferases [79]s u g g e s t
strongly that their actions and targets will be regulated
at a cell- and tissue- speciﬁc levels coincident with roles
in paracrine- and cell-speciﬁc events in atherothrombosis.
An a ¨ ıve impression might suggest that inhibition of ABO
glycotransferase functions, akin to the naturally occurring
ABO O blood group, might provide a therapeutic strategyInternational Journal of Vascular Medicine 9
for lowering the risk of thrombosis and CVD. However, such
a pharmacological approach would likely have untoward
hematological and immunological consequences and/or
nonspeciﬁc oﬀ target actions in cells and tissues not relevant
to vascular diseases. Identiﬁcation of the speciﬁc protein
and lipid targets of ABO which mediate the functional
eﬀects in thrombosis, atherosclerosis and CVD is likely
to provide greater opportunity for targeted therapeutic
development and clinical translation. Whether targeting
VWF carbohydrate modiﬁcations might provide clinically
meaningful opportunities for treatment of thrombosis and
MI is an open question.
There is much to be done to understand the role of ABO
and glycobiology in CVD, and the next decade should see
many advances in the basic biology, mechanistic actions,
and diagnostic, prognostic, and therapeutic possibilities in
humans. Thus, future studies to further deﬁne the associa-
tion between ABO blood groups and cardiovascular events
and risks, and to elucidate biochemical mechanisms respon-
sible for these associations, are not only of basic scientiﬁc
interest but also of translational clinical importance.
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